News | ASTRO | October 19, 2020

Varian Highlights Advancements in Intelligent Cancer Care at ASTRO20

Varian, a leading provider of cancer care technologies and solutions, continues to reinforce its commitment to delivering Intelligent Cancer Care during the 2020 American Society for Radiation Oncology (ASTRO) taking place virtually Oct. 24-31.

October 19, 2020 — Varian, a leading provider of cancer care technologies and solutions, continues to reinforce its commitment to delivering Intelligent Cancer Care during the 2020 American Society for Radiation Oncology (ASTRO) taking place virtually Oct. 24-31. At this year's show, the company will showcase its progress in helping more people access advanced cancer care, making cancer care more personalized, and delivering more data-driven insights to improve efficiencies and outcomes. In addition to a "best in class" virtual experience, Varian's contributions to Intelligent Cancer Care will be highlighted in eleven presentations including data from the use of Varian's adaptive radiotherapy system, Ethos, for lung, prostate, bladder, upper abdomen, head & neck cancers, and the first-look data presented by the recently-formed AI-driven Adaptive Intelligence Consortium.

"Despite the transition to a virtual platform, our entire global Varian team is looking forward to connecting with ASTRO 2020 attendees and showcasing our innovations that help providers deliver the best cancer care to patients throughout their entire journey," said Dow Wilson, Chief Executive Officer of Varian. "Since its launch at last year's ASTRO, our Ethos® Therapy has demonstrated significant impact toward personalizing treatment for patients resulting in 10 featured presentations during this year's meeting."

At this year's virtual event, Varian will participate with a dynamic booth presence and provide one-on-one product demonstrations, as well as highlight how it pioneers for the future with sessions during the ASTRO Innovation Hub. The company will also have a presence at the American Society of Radiologic Technologists (ASRT) and Society of Radiation Oncology Administrators (SROA) concurrent meetings. Attendees can register for all Varian educational and demo sessions at https://www.varian.com/resources-support/events/virtual-events.

ASTRO attendees will be able to view a variety of data presentations featuring Varian products and innovation. Registration links are available here: https://www.astro.org/Meetings-and-Education/Micro-Sites/2020/Annual-Meeting/Register.

Related Content

News | Radiation Therapy | May 06, 2021
May 6, 2021 — Individuals living with severe...
Research finds that a commonly used risk-prediction model for lung cancer does not accurately identify high-risk Black patients who could benefit from early screening

Getty Images

News | Lung Imaging | May 05, 2021
May 5, 2021 — Lung cancer is the third most common cance
The emergence of #therapeutic #radiopharmaceuticals and its adoption in #cancer care provide one more weapon in combating cancer

Getty Images

Feature | Radiation Oncology | May 04, 2021 | By Vinay Shivaprasad
The term nuclear medicine is associated with the diag
Despite receiving high radiation doses to their tumors, lung cancer patients treated with technique that spares a large part of the esophagus did not develop severe inflammation of the esophagus

Getty Images

News | Lung Imaging | April 30, 2021
April 30, 2021 — For many patients with localized lung cance...
#prostatecancer During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate cancer in Sweden than in previous years.

Getty Images

News | Prostate Cancer | April 30, 2021
April 30, 2021 — During the first wave of the corona pandemic, 36 percent fewer men were diagnosed with prostate canc
A 63-year-old multiple #myeloma patient, with skeletal pain. New #FDG avid axillary #lymphadenopathy 62 days (9 weeks) after second #mRNA #vaccination dose. Image used with permission of the Radiological Society of North America (#RSNA)

A 63-year-old multiple myeloma patient, with skeletal pain. New FDG avid axillary lymphadenopathy 62 days (9 weeks) after second mRNA vaccination dose. Image used with permission of the Radiological Society of North America (RSNA)

Feature | Coronavirus (COVID-19) | April 29, 2021 | By Melinda Taschetta-Millane
A phase 1 clinical trial led by investigators at the University of Chicago Medicine testing the effects of stereotactic body radiotherapy for treating multiple metastases has determined that treatments used for single tumors can also be safely used for treating patients with multiple metastases.

Image courtesy of Accuray

News | Stereotactic Body Radiation Therapy (SBRT) | April 23, 2021
April 23, 2021 — A phase 1 clinical trial led by investigators at the...